Drug Trial Radar · NCT06319820
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
641
Planned (sponsor's estimate)
Start
Apr 18, 2024
Primary completion
Jun 28, 2028
Study completion Dec 31, 2032
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Mar 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Conditions
- Non-Muscle Invasive Bladder Neoplasms
Interventions
TAR-210Combination product
TAR-210 will be administered intravesically.
GemcitabineDrug
Gemcitabine will be administered intravesically.
MMCDrug
MMC will be administered intravesically.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease Free Survival (DFS)Time frame: From randomization to the date of the first documented recurrence, disease progression or death (approximately 4 years and 2 months)
Locations
193 sites in 20 countries. Site status is shown where the registry gives one.
Arkansas Urology
Little Rock, Arkansas · Completed
Genesis Research LLC
Los Alamitos, California · Active not recruiting
USC Norris Comprehensive Cancer Center
Los Angeles, California · Active not recruiting
University of California Irvine Medical Center
Orange, California · Active not recruiting
Om Research LLC
San Diego, California · Active not recruiting
Genesis Research LLC 1
Sherman Oaks, California · Completed
University of Colorado Cancer Center Anschultz Cancer Pavilion
Aurora, Colorado · Completed
Colorado Clinical Research
Lakewood, Colorado · Active not recruiting
Mercy Research
San Luis, Colorado · Completed
Specialty Clinical Research of St Louis
San Luis, Colorado · Active not recruiting
Moffitt Cancer Center
Tampa, Florida · Active not recruiting
Northwestern University
Chicago, Illinois · Completed
First Urology
Jeffersonville, Indiana · Completed
Wichita Urology Group
Wichita, Kansas · Active not recruiting
Ochsner Health System
New Orleans, Louisiana · Active not recruiting
Chesapeake Urology Research Associates
Hanover, Maryland · Completed
Brigham And Women's Hospital
Boston, Massachusetts · Completed
Karmanos Cancer Institute
Detroit, Michigan · Active not recruiting
Comprehensive Urology
Royal Oak, Michigan · Active not recruiting
The Urology Center, PC
Omaha, Nebraska · Active not recruiting
Cancer Institute Of New Jersey
New Brunswick, New Jersey · Active not recruiting
Integrated Medical Professionals
New York, New York · Completed
Memorial Sloan Kettering Cancer Center
New York, New York · Active not recruiting
Associated Medical Professionals of Ny
Syracuse, New York · Active not recruiting
SUNY Upstate Med Univ
Syracuse, New York · Active not recruiting
Levine Cancer Institute
Charlotte, North Carolina · Active not recruiting
Associated Urologists of North Carolina
Raleigh, North Carolina · Active not recruiting
MidLantic Urology
Bala-Cynwyd, Pennsylvania · Completed
Keystone Urology Specialists
Lancaster, Pennsylvania · Active not recruiting
Carolina Urologic Research Center
Myrtle Beach, South Carolina · Active not recruiting
The Conrad Pearson Clinic
Germantown, Tennessee · Active not recruiting
University of Tennessee Medical Center
Knoxville, Tennessee · Completed
Urology Associates
Nashville, Tennessee · Active not recruiting
Urology Austin
Austin, Texas · Active not recruiting
Urology Clinics of North Texas
Dallas, Texas · Active not recruiting
UT Southwestern
Dallas, Texas · Completed
Houston Metro Urology
Houston, Texas · Active not recruiting
Spokane Urology
Spokane, Washington · Active not recruiting
Hospital Sirio Libanes
Buenos Aires, Argentina · Active not recruiting
Investigaciones Clinico Moleculares (ICM)
Chabas, Argentina · Active not recruiting
Showing 40 of 193 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.